Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000110465918062739/a18-36860_48k.htm
January 2023
January 2023
December 2022
November 2022
November 2022
August 2022
August 2022
June 2022
May 2022
April 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000110465918062739/a18-36860_48k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACRSEvents:
CIK: 1557746
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-062739
Submitted to the SEC: Thu Oct 18 2018 4:01:42 PM EST
Accepted by the SEC: Thu Oct 18 2018
Period: Wednesday, October 17, 2018
Industry: Pharmaceutical Preparations